Efficacy and safety of calcium acetate-magnesium carbonate in the treatment of hyperphosphatemia in dialysis patients
| Autor: | Hanene Elkateb, Malika Hajri, Hafedh Hedri, Imed Helal, Fethi Ben Hamida |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Every Two Weeks medicine.drug_class chemistry.chemical_element Parathyroid hormone lcsh:Medicine Calcium Gastroenterology Calcium Carbonate Phosphates Hyperphosphatemia Renal Dialysis Internal medicine Medicine Humans Prospective Studies business.industry Magnesium lcsh:R General Medicine medicine.disease Surgery Phosphate binder chemistry Parathyroid Hormone Kidney Failure Chronic Calcium acetate/magnesium carbonate Hypermagnesemia business medicine.drug |
| Zdroj: | Saudi Journal of Kidney Diseases and Transplantation, Vol 27, Iss 6, Pp 1162-1167 (2016) |
| ISSN: | 1319-2442 |
| Popis: | A phosphate binder combining calcium and magnesium offers an interesting therapeutic option to control hyperphosphatemia in dialysis patients. We investigated the effectiveness and tolerance of calcium acetate-magnesium carbonate (Ca-Mg). This is a 16-week prospective study including 16 dialysis patients. After an initial two-week washout period, serum phosphorus (sPho) ≥1.8 mmol/L, serum calcium (sCa) ≤2.6 mmol/L, and serum magnesium ≤1.5 mmol/L were the main inclusion criteria. The initial dose of Ca-Mg depended on sPho level and was titrated for every two weeks to have a sPho ≤ 1.8 mmol/L. A second two-week washout period followed the 12 weeks of treatment. Ca-Mg significantly reduced the mean sPho levels from 2.14 to 1.75 mmol/L by the end of the 12-week treatment period (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|